[ @entity2390 in the treatment of advanced XXXX . Preliminary study].

@entity1 @entity788 @entity5 @entity490 @entity2390 @entity1943
BACKGROUND: Data from experimental studies suggest that @entity2390 , the long acting @entity1943 analogue, improves survival of animals with @entity788 . To assess the antitumour effect of @entity2390 , a randomized trial was performed comparing @entity2390 with supportive care in advanced @entity788 @entity1 . All @entity1 , aged 59-75 years, were not liable to radical surgical treatment and were not submitted to other treatments (chemo and/or radiotherapy). METHODS: Six @entity1 were enrolled, 4 of these treated with @entity2390 (500 micrograms two times a day subcutaneous for six months) and the other 2 were inserted a control group. RESULTS: The @entity1 treated with @entity2390 showed a significant advantage in quality of life (restored appetite, improvement of digestion and intestine function, remission of @entity490 and preservation of baseline body weight) with a mean > 80 of karnofsky performance score. Monitoring of @entity5 size changes (US-TC) over the 6 months study period, showed slackened @entity5 in all treated @entity1 , whereas @entity5 grew according to an almost exponential trend in untreated @entity1 . Also survival was better in treated @entity1 : in particular, 2 @entity1 out of 4 who completed the study underwent follow-up until they died 12 and 16 months after beginning of treatment, respectively. Karnofsky performance score was particularly high in both @entity1 . This supports the view that @entity2390 is endowed with antiproliferative activity. CONCLUSION: In conclusion @entity2390 therapy seems to confer a survival benefit and a better quality of life in advanced @entity5 . Additional studies are needed to confirm these results and to clarify other questions about dose and @entity1943 receptors in this kind of @entity5 .
